Analysis Indicates BG Medicine's Galectin-3 Test is Predictive of Hospital Readmissions | GenomeWeb

BG Medicine this week announced results from an analysis of three multicenter clinical research trials that indicate its BGM Galectin-3 test is predictive of rehospitalization for heart failure within the first 30 days following discharge from an initial hospital stay.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The Wall Street Journal reports that Walgreens didn't fully vet Theranos before entering partnership.

Jeremy Berg is to be the next editor in chief of Science magazine.

Regeneron Pharmaceuticals is to be the new sponsor of the prestigious high school Science Talent Search competition, according to the New York Times.

In Nature this week: genetic mechanism through which some cancers evade the immune system, and more.